182 related articles for article (PubMed ID: 38259266)
1. An updated review of experimental rodent models of pulmonary hypertension and left heart disease.
Jasińska-Stroschein M
Front Pharmacol; 2023; 14():1308095. PubMed ID: 38259266
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
3. Animal models of pulmonary hypertension due to left heart disease.
Liu SF; Yan Y
Animal Model Exp Med; 2022 Sep; 5(3):197-206. PubMed ID: 35234367
[TBL] [Abstract][Full Text] [Related]
4. A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats.
Sang P; Kucherenko MM; Yao J; Li Q; Simmons S; Kuebler WM; Knosalla C
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35311828
[TBL] [Abstract][Full Text] [Related]
5. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
Joshi SR; Atabay EK; Liu J; Ding Y; Briscoe SD; Alexander MJ; Andre P; Kumar R; Li G
Front Cardiovasc Med; 2023; 10():1064290. PubMed ID: 36910526
[TBL] [Abstract][Full Text] [Related]
6. Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice.
Joki Y; Konishi H; Takasu K; Minamino T
J Cardiol; 2023 Apr; 81(4):347-355. PubMed ID: 36244565
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.
Ranchoux B; Nadeau V; Bourgeois A; Provencher S; Tremblay É; Omura J; Coté N; Abu-Alhayja'a R; Dumais V; Nachbar RT; Tastet L; Dahou A; Breuils-Bonnet S; Marette A; Pibarot P; Dupuis J; Paulin R; Boucherat O; Archer SL; Bonnet S; Potus F
Circ Res; 2019 Aug; 125(4):449-466. PubMed ID: 31154939
[TBL] [Abstract][Full Text] [Related]
8. Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?
Papathanasiou A; Nakos G
World J Crit Care Med; 2015 Nov; 4(4):274-7. PubMed ID: 26557477
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of pulmonary hypertension caused by left heart disease.
Xiao M; Lai D; Yu Y; Wu Q; Zhang C
Front Cardiovasc Med; 2023; 10():1079142. PubMed ID: 36937903
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease.
Charalampopoulos A; Lewis R; Hickey P; Durrington C; Elliot C; Condliffe R; Sabroe I; Kiely DG
Front Med (Lausanne); 2018; 5():174. PubMed ID: 29928642
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review.
Kido K; Coons JC
Pharmacotherapy; 2019 Sep; 39(9):929-945. PubMed ID: 31349390
[TBL] [Abstract][Full Text] [Related]
14. Training programs in preclinical studies. The example of pulmonary hypertension. Systematic review and meta-analysis.
Jasińska-Stroschein M
PLoS One; 2022; 17(11):e0276875. PubMed ID: 36378649
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary hypertension due to left heart diseases.
Vachiéry JL; Adir Y; Barberà JA; Champion H; Coghlan JG; Cottin V; De Marco T; Galiè N; Ghio S; Gibbs JS; Martinez F; Semigran M; Simonneau G; Wells A; Seeger W
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D100-8. PubMed ID: 24355634
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of pulmonary hypertension in left heart disease.
Breitling S; Ravindran K; Goldenberg NM; Kuebler WM
Am J Physiol Lung Cell Mol Physiol; 2015 Nov; 309(9):L924-41. PubMed ID: 26502478
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient.
Ibe T; Wada H; Sakakura K; Ikeda N; Yamada Y; Sugawara Y; Mitsuhashi T; Ako J; Fujita H; Momomura S
J Cardiol; 2016 Jun; 67(6):555-9. PubMed ID: 26299611
[TBL] [Abstract][Full Text] [Related]
18. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
Poulsen SH
Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.
Al-Omary MS; Sugito S; Boyle AJ; Sverdlov AL; Collins NJ
Hypertension; 2020 Jun; 75(6):1397-1408. PubMed ID: 32336230
[TBL] [Abstract][Full Text] [Related]
20. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review.
Dzudie A; Kengne AP; Thienemann F; Sliwa K
BMJ Open; 2014 Jul; 4(7):e004843. PubMed ID: 25011987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
